In a nutshell This study evaluated the long-term outcomes of docetaxel (Taxotere) plus hormone therapy for patients with metastatic prostate cancer (cancer that spread outside the prostate). This study found that this treatment combination improved survival for these patients, regardless of tumor burden. Some background One treatment for...
Read MoreIn a nutshell This trial is examining the safety and effectiveness of cabazitaxel (Jevtana) with abiraterone acetate (Zytiga) compared to abiraterone acetate alone for metastatic (cancer that has spread) castration-resistant prostate cancer (cancer that is no longer responding to hormone therapy). The main outcome measured will be the...
Read More
In a nutshell This study aimed to compare quality of life between patients with metastatic prostate cancer who were treated with androgen deprivation therapy (ADT) and docetaxel and those who were treated with ADT alone. This study found that ADT and docetaxel was associated with statistically worse QOL at 3 months. However, QOL was better...
Read More
In a nutshell The authors aimed to determine whether hormone drugs abiraterone (Zytiga) and enzalutamide (Xtandi) and chemotherapy drug cabazitaxel (Jevtana) improved overall survival (patients who were still alive after treatment) in prostate cancer patients with advanced, hormone-resistant (castration-resistant) prostate...
Read More
In a nutshell The authors determined how body weight could influence patient outcome following docetaxel (Taxotere) treatment in patients with metastatic cancer (that has spread) prostate cancer. Some background Advanced prostate cancer is cancer that has spread outside the prostate gland to different organs. Many advanced...
Read MoreIn a nutshell The authors aimed to determine the impact of docetaxel on patient quality of life. Some background Metastatic cancer is cancer that has spread around the body from the primary tumor site. Docetaxel (Taxotere, Docecad) is a chemotherapy drug used to treat lung, prostate, breast, stomach and head/neck cancer by preventing cancer...
Read MoreIn a nutshell The authors aimed to determine the tumor activity and safety of cabazitaxel (Jevtana) and abiraterone (Zytiga) when used in metastatic castrate-resistant patients (patients whose cancer has spread and no longer responds to hormone therapy) who had previously received docetaxel (Taxotere, Docecad) treatment. Some...
Read More
